XDXianhui Dong

Xianhui Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xianhui Dong has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative mortality outcomes in metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease subtypes in the United States

    by Pengwei Zhang, Sijia Yang, Rong Hu, Tianfang Peng, Peipei Yu, Yijun Zeng, Chunhong Ye, Panpan Wang, Xianhui Dong, Zhiying Che

    Background: In 2023, experts from the European and American regions proposed the concepts of steatotic liver disease (SLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD was proposed as a replacement for nonalcoholic fatty liver disease (NAFLD). We compared the long-term outcomes of patients with MASLD, NAFLD, and various subtypes of SLD. Methods: We conducted a retrospective study using the NHANESIII database. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality and cause-specific mortality among patients with subtypes of SLD, MASLD, and NAFLD. Results: During a follow-up period of 31 years (median 25 years), the adjusted risks of all-cause death for patients with MASLD was 1.19 (95% CI 1.06–1.34; P = 0.006) vs . the non-SLD group. There was a moderate level of consistency between MASLD and NAFLD (Cohen’s kappa coefficient of 0.62545). Advanced fibrosis was the most serious risk factor for all-cause mortality in MASLD, and high C-reactive protein concentration was the most serious risk factor for all-cause mortality in NAFLD, followed by type 2 diabetes. Conclusions: MASLD is associated with a higher risk of all-cause mortality, and this association is independent of patients’ demographic or metabolic characteristics, despite a relatively small hazard ratio. Our research findings further support that MASLD is a pathological disease related to liver disease itself. Therefore, redefining NAFLD as MASLD may help improve our understanding of predictive factors that increase the risk of death.


  • Open Access

    Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals

    by Pengwei Zhang, Yijun Zeng, Sijia Yang, Chunhong Ye, Mingwei Wang, Tianfang Peng, Li Li, Xianhui Dong

    The difference in the survival of obese patients and normal-weight/lean patients with diabetic MAFLD remains unclear. Therefore, we aimed to describe the long-term survival of individuals with diabetic MAFLD and overweight/obesity (OT2M), diabetic MAFLD with lean/normal weight (LT2M), MAFLD with overweight/obesity and without T2DM (OM), and MAFLD with lean/normal weight and without T2DM (LM). Using the NHANESIII database, participants with MAFLD were divided into four groups. Hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause, cardiovascular disease (CVD)-related, and cancer-related mortalities for different MAFLD subtypes were evaluated using Cox proportional hazards models. Of the 3539 participants, 1618 participants (42.61%) died during a mean follow-up period of 274.41 ± 2.35 months. LT2M and OT2M had higher risks of all-cause mortality (adjusted HR, 2.14; 95% CI 1.82–2.51; p < 0.0001; adjusted HR, 2.24; 95% CI 1.32–3.81; p = 0.003) and CVD-related mortality (adjusted HR, 3.25; 95% CI 1.72–6.14; p < 0.0001; adjusted HR, 3.36; 95% CI 2.52–4.47; p < 0.0001) than did OM. All-cause and CVD mortality rates in LT2M and OT2M patients were higher than those in OM patients. Patients with concurrent T2DM and MAFLD should be screened, regardless of the presence of obesity.


  • Open Access

    A personalized prognostic model for long-term survival in patients with intrahepatic cholangiocarcinoma: a retrospective cohort study

    by Xianhui Dong, Pengwei Zhang, Chunhong Ye, Li Li

    Dong X, et al. Ann Surg Treat Res. 2024 Jul;107(1):16-26. https://doi.org/10.4174/astr.2024.107.1.16